Maxigesic approval positive for AFT Pharmaceuticals

Maxigesic approval positive for AFT Pharmaceuticals
AFT founder and managing director Hartley Atkinson. (Image: Supplied)
Tamara Poi-Ngawhika
 AFT Pharmaceuticals, the owner of Maxigesic, offers investors a “large opportunity but with a high degree of uncertainty”, according to Forsyth Barr analysts.The New Zealand stock exchange-listed company has just announced its rapid-release tablet form of Maxigesic has been granted approval by the United States Food and Drug Administration (FDA) for use in the country.Breaking into the US market is difficult because getting FDA approval can be challenging. AFT said the US market is worth about US$7.16 billion (NZ$11.5b) and is...

More Markets

NZ sharemarket lifts off after Auckland Airport numbers
Markets Market close

NZ sharemarket lifts off after Auckland Airport numbers

The S&P/NZX 50 Index closed at 12,943.57, gaining 59.19 points or 0.46%.

Auckland Airport numbers bounce back
Markets

Auckland Airport numbers bounce back

Numbers highest since the pandemic hit five years ago.

NZD outlook: 2025 more about surviving
Markets

NZD outlook: 2025 more about surviving

The kiwi shed more than 11% in 2024, and we already see more downsides. 

Rate decision odds are tight, NZD set for a wild ride
Markets Best of BusinessDesk

Rate decision odds are tight, NZD set for a wild ride

It did turn out to be an understatement.